Submitted:
31 July 2025
Posted:
01 August 2025
You are already at the latest version
Abstract
Keywords:
1. Introduction
2. Results
2.1. Fundamental Theory—Kinetic-Thermodynamic Coupling in the Glycolytic Pathway
- the enzyme’s total concentration or activity, and
- the concentration of its substrate.
- X0 is the initial substrate,
- Xn is the final product
- Xk (for k =1,2,3,…,n−1) is both the product of reaction k and the substrate of reaction k+1.
- the enzyme’s total activity, and
- the thermodynamic equilibrated concentrations of its substrate.
2.2. Kinetic-Thermodynamic Coupling in the Regulation of Glycolysis by PKM2
- Because the thermodynamic properties of glycolysis govern intermediate distributions, this profile is conserved across cell types[4,5,6,7]. Among the 11 glycolytic reactions, three catalyzed by hexokinase 2 (HK2), phosphofructokinase-1 (PFK1), and pyruvate kinase (PK) operate far from equilibrium, and thus provide the primary thermodynamic driving force for glycolysis. The remaining reactions are at near-equilibrium state. The lactate dehydrogenase (LDH) reaction is also exergonic in cancer cells, with an average ΔG of ~–7 kJ/mol. Because the ΔG profile is conserved across diverse cell types, the thermodynamic regulation of metabolite concentrations is systemically stable.
- When PKM2 is knockdown by 80%, it does not change the above thermodynamic features of glycolytic pathway [6].
- However, PKM2 knockdown does induce a redistribution of Gibbs free energy in the glycolytic pathway: the value of the Gibbs free energy of PKM2-catalyzed reaction (ΔGPKM2) becomes more negative (from ~ -25 kJ/mol to ~ -28 kJ/mol); while the value of the Gibbs free energy of PFK1-catalyzed reaction (ΔGPFK1) becomes less negative (from ~ -15 kJ/mol to ~-12 kJ/mol); ΔG values for other steps remain unchanged; this redistribution of Gibbs free energy in the pathway leads to proportional increase of the intermediates (PEP, 2-PG, 3-PG, GA3P, DHAP, and FBP) in the segment between PFK1 and PKM2 increases proportionally, while does not change the concentration of F6P, G6P, and pyruvate.
- Obviously, the changes of values of ΔGPKM2 and ΔGPFK1 do not change their thermodynamic nature, i.e., the reactions are still far from equilibrium.
- Despite that PKM2 knockdown markedly reduces the PKM2t, it did not change PKM2a.
- Glucose consumption and lactate production, i.e., the glycolytic flux, remain constant despite the 80% change of PKM2t.
- Steady state a, where PKM2t is high, and
- Steady state b, where PKM2t is low.
- PKM2t changes leads to a transfer of a fraction of the free energy between PKM2 catalyzed reaction and PFK1 catalyzed reaction.
- When PKM2t decreases, a fraction of free energy is transferred from to ; conversely, when PKM2t increases, a fraction of free energy is transferred from to .
- The increase in the value of is equal to the decrease in the value of , and vice versa.
- The changes of the concentrations of intermediates are strictly controlled by the amount of free energy transferred between PKM2-catalyzed and PFK1-catalyzed reactions.
- The large negative values of ∆GPFK1 lays the theoretical basis for the concentration of [G6P] and [F6P] not to be disturbed by the downstream perturbation. The stability of [G6P] is especially important because G6P is a strong allosteric inhibitor of HK2. Preventing changes in [G6P] ensures that HK2 activity remains stable, and thus the glycolytic input is preserved. In this way, the large negative values of ΔGPFK1 functions as a thermodynamic insulator, maintaining input stability despite downstream disturbances.
- As PKM2t changes, opposing changes in [PEP] and [FBP] stabilize PKM2a. Thus, despite large changes in PKM2t, PKM2a remains stable, due to the compensatory shifts in substrate concentration.
- As PKM2a remains constant, glycolytic rate at steady state a and steady state b remains constant.
2.3. Quantitative Coupling of PKM2 Kinetics with Thermodynamics in the Glycolytic Pathway
- PKM2 kinetics is tightly coupled with thermodynamics of the glycolytic pathway.
- When [PKM2] or PKM2t decreases, ΔGPKM2 becomes more negative, ΔGPFK1 becomes less negative, and [PEP] increases.
- When [PKM2] or PKM2t increases, ΔGPKM2 becomes less negative, ΔGPFK1 becomes more negative, and [PEP] decreases.
- This reciprocal changes of ΔGPKM2 and ΔGPFK1 in the glycolytic pathway are the basis for the reciprocal changes of PKM2t and [PEP], that maintains PKM2a and glycolytic rate constant despite the marked change of PKM2t.

2.4. Transient Interstate Between Any Two Steady States
- m denotes the total amount of substrate processed by PKM2 during the transition
- v̅ denotes the average catalytic velocity of PKM2 during the transition
- t denotes the time required to complete the transition
- Instantaneous changes in PKM2t, or
- Stepwise changes across n discrete steps.
|
Kcat[PKM2]a (μmol/min∙mg protein) (before PKM2 KD) |
3387 |
|
Kcat[PKM2]b (μmol/min∙mg protein) (after PKM2 KD) |
1012 |
| mg protein/l cells | 282000 |
| Kcat[PKM2]a (μmol/min∙l cells) | 955134000 |
| Kcat[PKM2]b (μmol/min∙l cells) | 285666000 |
| K0.5 (μM) | 74 |
| [PEP]a (μM) (before PKM2 KD) | 67 |
| [PEP]b (μM) (after PKM2 KD) | 215 |
| ∆[PEP] (μM) | 148 |
| v̅ (μmol/min∙l cells) | 183159000 |
| t (ms) | 0.049 |
| m (μmol/l cells) | 150 |
2.5. PKM2’s Flux Control Coefficient and Intermediate Concentration Control Coefficient
- FCC quantifies an enzyme's influence on the flux through the pathway.
- CCC quantifies its influence on the concentration of a given intermediate.
2.6. Flux Control Coefficient (FCC) of PKM2
2.7. Concentration Control Coefficient (CCC) of PKM2
- The ΔG of the PFK1 reaction insulating upstream segments
- The final step (LDH) maintaining pyruvate homeostasis
3. Discussion
- −
- Reciprocal shifts in ΔGPKM2 and ΔGPFK1
- −
- Proportional changes in intermediate concentrations between PFK1 and PKM2
- −
- Stability of upstream ([G6P], [F6P]) and downstream ([pyruvate]) metabolites
- −
- An inverse correlation between PKM2t and [PEP] that preserves PKM2a

4. Methods
Funding and additional information
Data Availability Statement
Conflicts of Interest
References
- Jia, D.; Lu, M.; Jung, K. H. , Park, J. H., Yu, L., Onuchic, J. N., Kaipparettu, B. A., and Levine, H. Elucidating cancer metabolic plasticity by coupling gene regulation with metabolic pathways. Proc Natl Acad Sci U S A 2019, 116, 3909–3918. [Google Scholar] [CrossRef] [PubMed]
- Fendt, S. M. , Frezza, C., and Erez, A. Targeting Metabolic Plasticity and Flexibility Dynamics for Cancer Therapy. Cancer Discov 2020, 10, 1797–1807. [Google Scholar] [CrossRef] [PubMed]
- Parlani, M.; Jorgez, C.; Friedl, P. Plasticity of cancer invasion and energy metabolism. Trends Cell Biol 2023, 33, 388–402. [Google Scholar] [CrossRef] [PubMed]
- Jin, C.; Zhu, X.; Wu, H.; Wang, Y.; Hu, X. Perturbation of phosphoglycerate kinase, 1 (PGK1) only marginally affects glycolysis in cancer cells. J Biol Chem 2020, 295, 6425–6446. [Google Scholar] [CrossRef]
- Zhu, X.; Jin, C.; Pan, Q.; Hu, X. Determining the quantitative relationship between glycolysis and GAPDH in cancer cells exhibiting the Warburg effect. J Biol Chem 2021, 296, 100369. [Google Scholar] [CrossRef]
- Jin, C.; Hu, W.; Wang, Y.; Wu, H.; Zeng, S.; Ying, M.; Hu, X. Deciphering the interaction between PKM2 and the built-in thermodynamic properties of the glycolytic pathway in cancer cells. J Biol Chem 2024, 300, 107648. [Google Scholar] [CrossRef]
- Zeng, S.; Wang, Y.; Ying, M.; Jin, C.; Ying, C.; Wang, D.; Wu, H.; Hu, X. (2024) Elucidating the kinetic and thermodynamic insight into regulation of glycolysis by lactate dehydrogenase and its impact on tricarboxylic acid cycle and oxidative phosphorylation in cancer cells. eLife Sciences Publications, Ltd.
- de, W.i.t. R. H. , Mujic-Delic, A., van Senten, J. R., Fraile-Ramos, A., Siderius, M., and Smit, M. J. Human cytomegalovirus encoded chemokine receptor US28 activates the HIF-1alpha/PKM2 axis in glioblastoma cells. Oncotarget 2016, 7, 67966–67985. [Google Scholar]
- Yang, L.; Hou, Y.; Yuan, J.; Tang, S.; Zhang, H.; Zhu, Q.; Du, Y. E. , Zhou, M., Wen, S., Xu, L., Tang, X., Cui, X., and Liu, M. Twist promotes reprogramming of glucose metabolism in breast cancer cells through PI3K/AKT and p53 signaling pathways. Oncotarget 2015, 6, 25755–25769. [Google Scholar] [CrossRef]
- Sun, Q.; Chen, X.; Ma, J.; Peng, H.; Wang, F.; Zha, X.; Wang, Y.; Jing, Y.; Yang, H.; Chen, R.; Chang, L.; Zhang, Y.; Goto, J.; Onda, H.; Chen, T.; Wang, M. R. , Lu, Y., You, H., Kwiatkowski, D., and Zhang, H. Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth. Proc Natl Acad Sci U S A 2011, 108, 4129–4134. [Google Scholar] [CrossRef]
- Panasyuk, G.; Espeillac, C.; Chauvin, C.; Pradelli, L. A. , Horie, Y., Suzuki, A., Annicotte, J. S., Fajas, L., Foretz, M., Verdeguer, F., Pontoglio, M., Ferre, P., Scoazec, J. Y., Birnbaum, M. J., Ricci, J. E., and Pende, M. PPARgamma contributes to PKM2 and HK2 expression in fatty liver. Nat Commun 2012, 3, 672. [Google Scholar] [CrossRef]
- Wu, M.; An, J.; Zheng, Q.; Xin, X.; Lin, Z.; Li, X.; Li, H.; Lu, D. Double mutant P53 (N340Q/L344R) promotes hepatocarcinogenesis through upregulation of Pim1 mediated by PKM2 and LncRNA CUDR. Oncotarget 2016, 7, 66525–66539. [Google Scholar] [CrossRef]
- Shang, Y.; He, J.; Wang, Y.; Feng, Q.; Zhang, Y.; Guo, J.; Li, J.; Li, S.; Wang, Y.; Yan, G.; Ren, F.; Shi, Y.; Xu, J.; Zeps, N.; Zhai, Y.; He, D.; Chang, Z. CHIP/Stub1 regulates the Warburg effect by promoting degradation of PKM2 in ovarian carcinoma. Oncogene 2017, 36, 4191–4200. [Google Scholar] [CrossRef]
- Xu, Q.; Liu, L. Z. , Yin, Y., He, J., Li, Q., Qian, X., You, Y., Lu, Z., Peiper, S. C., Shu, Y., and Jiang, B. H. Regulatory circuit of PKM2/NF-kappaB/miR-148a/152-modulated tumor angiogenesis and cancer progression. Oncogene 2015, 34, 5482–5493. [Google Scholar] [CrossRef]
- Zhang, L. F. , Lou, J. T., Lu, M. H., Gao, C., Zhao, S., Li, B., Liang, S., Li, Y., Li, D., and Liu, M. F. Suppression of miR-199a maturation by HuR is crucial for hypoxia-induced glycolytic switch in hepatocellular carcinoma. EMBO J 2015, 34, 2671–2685. [Google Scholar] [CrossRef]
- Guo, M.; Zhao, X.; Yuan, X.; Jiang, J.; Li, P. MiR-let-7a inhibits cell proliferation, migration, and invasion by down-regulating PKM2 in cervical cancer. Oncotarget 2017, 8, 28226–28236. [Google Scholar] [CrossRef] [PubMed]
- Li, H.; Li, J.; Jia, S.; Wu, M.; An, J.; Zheng, Q.; Zhang, W.; Lu, D. miR675 upregulates long noncoding RNA H19 through activating EGR1 in human liver cancer. Oncotarget 2015, 6, 31958–31984. [Google Scholar] [CrossRef]
- Morgan, H. P. , O'Reilly, F. J., Wear, M. A., O'Neill, J. R., Fothergill-Gilmore, L. A., Hupp, T., and Walkinshaw, M. D. M2 pyruvate kinase provides a mechanism for nutrient sensing and regulation of cell proliferation. Proc Natl Acad Sci U S A 2013, 110, 5881–5886. [Google Scholar] [CrossRef] [PubMed]
- Sparmann, G.; Schulz, J.; Hofmann, E. Effects of L-alanine and fructose (1,6-diphosphate) on pyruvate kinase from ehrlich ascites tumour cells. FEBS Lett 1973, 36, 305–308. [Google Scholar] [CrossRef]
- Yuan, M.; McNae, I. W. , Chen, Y., Blackburn, E. A., Wear, M. A., Michels, P. A. M., Fothergill-Gilmore, L. A., Hupp, T., and Walkinshaw, M. D. An allostatic mechanism for M2 pyruvate kinase as an amino-acid sensor. Biochem J 2018, 475, 1821–1837. [Google Scholar] [CrossRef]
- Dombrauckas, J. D. , Santarsiero, B. D., and Mesecar, A. D. Structural basis for tumor pyruvate kinase M2 allosteric regulation and catalysis. Biochemistry 2005, 44, 9417–9429. [Google Scholar] [CrossRef]
- Chaneton, B.; Hillmann, P.; Zheng, L.; Martin, A.C. L. , Maddocks, O. D. K., Chokkathukalam, A., Coyle, J. E., Jankevics, A., Holding, F. P., Vousden, K. H., Frezza, C., O'Reilly, M., and Gottlieb, E. Serine is a natural ligand and allosteric activator of pyruvate kinase M2. Nature 2012, 491, 458–462. [Google Scholar] [CrossRef]
- Keller, K. E. , Tan, I. S., and Lee, Y. S. SAICAR stimulates pyruvate kinase isoform M2 and promotes cancer cell survival in glucose-limited conditions. Science 2012, 338, 1069–1072. [Google Scholar] [CrossRef]
- Hitosugi, T.; Kang, S.; Vander Heiden, M. G. , Chung, T. W., Elf, S., Lythgoe, K., Dong, S., Lonial, S., Wang, X., Chen, G. Z., Xie, J., Gu, T. L., Polakiewicz, R. D., Roesel, J. L., Boggon, T. J., Khuri, F. R., Gilliland, D. G., Cantley, L. C., Kaufman, J., and Chen, J. Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth. Sci Signal.
- Presek, P.; Reinacher, M.; Eigenbrodt, E. Pyruvate kinase type M2 is phosphorylated at tyrosine residues in cells transformed by Rous sarcoma virus. FEBS Lett 1988, 242, 194–198. [Google Scholar] [CrossRef]
- Bettaieb, A.; Bakke, J.; Nagata, N.; Matsuo, K.; Xi, Y.; Liu, S.; AbouBechara, D.; Melhem, R.; Stanhope, K.; Cummings, B.; Graham, J.; Bremer, A.; Zhang, S.; Lyssiotis, C. A. , Zhang, Z. Y., Cantley, L. C., Havel, P. J., and Haj, F. G. Protein tyrosine phosphatase, 1B regulates pyruvate kinase M2 tyrosine phosphorylation. J Biol Chem 2013, 288, 17360–17371. [Google Scholar] [CrossRef] [PubMed]
- Christofk, H. R. , Vander Heiden, M. G., Wu, N., Asara, J. M., and Cantley, L. C. Pyruvate kinase M2 is a phosphotyrosine-binding protein. Nature 2008, 452, 181–186. [Google Scholar] [CrossRef] [PubMed]
- Yang, W.; Zheng, Y.; Xia, Y.; Ji, H.; Chen, X.; Guo, F.; Lyssiotis, C. A. , Aldape, K., Cantley, L. C., and Lu, Z. ERK1/2-dependent phosphorylation and nuclear translocation of PKM2 promotes the Warburg effect. Nat Cell Biol 2012, 14, 1295–1304. [Google Scholar] [CrossRef] [PubMed]
- Park, Y. S. , Kim, D. J., Koo, H., Jang, S. H., You, Y. M., Cho, J. H., Yang, S. J., Yu, E. S., Jung, Y., Lee, D. C., Kim, J. A., Park, Z. Y., Park, K. C., and Yeom, Y. I. AKT-induced PKM2 phosphorylation signals for IGF-1-stimulated cancer cell growth. Oncotarget 2016, 7, 48155–48167. [Google Scholar] [CrossRef]
- Lee, K. M. , Nam, K., Oh, S., Lim, J., Lee, T., and Shin, I. ECM1 promotes the Warburg effect through EGF-mediated activation of PKM2. Cell Signal 2015, 27, 228–235. [Google Scholar] [CrossRef]
- Lv, L.; Li, D.; Zhao, D.; Lin, R.; Chu, Y.; Zhang, H.; Zha, Z.; Liu, Y.; Li, Z.; Xu, Y.; Wang, G.; Huang, Y.; Xiong, Y.; Guan, K. L. , and Lei, Q. Y. Acetylation targets the M2 isoform of pyruvate kinase for degradation through chaperone-mediated autophagy and promotes tumor growth. Mol Cell 2011, 42, 719–730. [Google Scholar] [CrossRef]
- Lv, L.; Xu, Y. P. , Zhao, D., Li, F. L., Wang, W., Sasaki, N., Jiang, Y., Zhou, X., Li, T. T., Guan, K. L., Lei, Q. Y., and Xiong, Y. Mitogenic and oncogenic stimulation of K433 acetylation promotes PKM2 protein kinase activity and nuclear localization. Mol Cell 2013, 52, 340–352. [Google Scholar] [CrossRef]
- Park, S. H. , Ozden, O., Liu, G., Song, H. Y., Zhu, Y., Yan, Y., Zou, X., Kang, H. J., Jiang, H., Principe, D. R., Cha, Y. I., Roh, M., Vassilopoulos, A., and Gius, D. SIRT2-Mediated Deacetylation and Tetramerization of Pyruvate Kinase Directs Glycolysis and Tumor Growth. Cancer Res 2016, 76, 3802–3812. [Google Scholar]
- Luo, W.; Hu, H.; Chang, R.; Zhong, J.; Knabel, M.; O'Meally, R.; Cole, R. N. , Pandey, A., and Semenza, G. L. Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor, 1. Cell 2011, 145, 732–744. [Google Scholar] [CrossRef] [PubMed]
- Wang, J.; Yang, P.; Yu, T.; Gao, M.; Liu, D.; Zhang, J.; Lu, C.; Chen, X.; Zhang, X.; Liu, Y. Lactylation of PKM2 Suppresses Inflammatory Metabolic Adaptation in Pro-inflammatory Macrophages. Int J Biol Sci 2022, 18, 6210–6225. [Google Scholar] [CrossRef] [PubMed]
- Iqbal, M. A. , Siddiqui, F. A., Gupta, V., Chattopadhyay, S., Gopinath, P., Kumar, B., Manvati, S., Chaman, N., and Bamezai, R. N. Insulin enhances metabolic capacities of cancer cells by dual regulation of glycolytic enzyme pyruvate kinase M2. Mol Cancer 2013, 12, 72. [Google Scholar] [CrossRef] [PubMed]
- Anastasiou, D.; Poulogiannis, G.; Asara, J. M. , Boxer, M. B., Jiang, J. K., Shen, M., Bellinger, G., Sasaki, A. T., Locasale, J. W., Auld, D. S., Thomas, C. J., Vander Heiden, M. G., and Cantley, L. C. Inhibition of pyruvate kinase M2 by reactive oxygen species contributes to cellular antioxidant responses. Science 2011, 334, 1278–1283. [Google Scholar] [PubMed]
- Liu, F.; Ma, F.; Wang, Y.; Hao, L.; Zeng, H.; Jia, C.; Wang, Y.; Liu, P.; Ong, I. M. , Li, B., Chen, G., Jiang, J., Gong, S., Li, L., and Xu, W. PKM2 methylation by CARM1 activates aerobic glycolysis to promote tumorigenesis. Nat Cell Biol 2017, 19, 1358–1370. [Google Scholar] [CrossRef]
- Wang, Y.; Liu, J.; Jin, X.; Zhang, D.; Li, D.; Hao, F.; Feng, Y.; Gu, S.; Meng, F.; Tian, M.; Zheng, Y.; Xin, L.; Zhang, X.; Han, X.; Aravind, L.; Wei, M. O-GlcNAcylation destabilizes the active tetrameric PKM2 to promote the Warburg effect. Proc Natl Acad Sci U S A 2017, 114, 13732–13737. [Google Scholar] [CrossRef]
- Macpherson, J. A. , Theisen, A., Masino, L., Fets, L., Driscoll, P. C., Encheva, V., Snijders, A. P., Martin, S. R., Kleinjung, J., Barran, P. E., Fraternali, F., and Anastasiou, D. Functional cross-talk between allosteric effects of activating and inhibiting ligands underlies PKM2 regulation. Elife 2019, 8. [Google Scholar]
- Wang, Y.; Wu, H.; Hu, X. Quantification of the inputs and outputs of serine and glycine metabolism in cancer cells. Arch Biochem Biophys 2025, 768, 110367. [Google Scholar] [CrossRef]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).